Last updated: March 25, 2026
Tirzepatide (Mounjaro/Zepbound) produced average weight loss of 22.5% over 72 weeks in Phase 3 trials — the highest of any FDA-approved obesity medication. As a dual GIP/GLP-1 agonist, it outperforms semaglutide by approximately 7–8 percentage points in head-to-head comparable data.
A visual breakdown of the landmark SURMOUNT-1 trial for Eli Lilly's first-in-class dual incretin — now FDA-approved as Mounjaro & Zepbound.
Mechanism of Action
Tirzepatide simultaneously activates two metabolic receptors — the first approved drug to combine GIP and GLP-1 targeting. Here's what each does.
Controls appetite, slows gastric emptying, and enhances insulin secretion in response to meals. This is the same target as semaglutide (Ozempic/Wegovy) — a proven weight-loss mechanism in hundreds of thousands of patients.
Glucose-dependent insulinotropic polypeptide receptor. Boosts insulin sensitivity, enhances fat metabolism, and amplifies the GLP-1 effect. This second target is what gives tirzepatide its edge over GLP-1-only drugs like semaglutide.
By hitting both GIP and GLP-1 receptors simultaneously, tirzepatide creates a synergistic effect greater than either alone. This dual incretin approach delivered significantly more weight loss than semaglutide in cross-trial comparisons, establishing a new standard of care.
SURMOUNT-1 Data
Average percent body weight lost across all dose groups at 72 weeks. Bars animate when you scroll to this section.
72-Week Outcomes
Percentage of participants achieving meaningful weight loss thresholds at 72 weeks. The consistency across doses is remarkable.
Competitive Landscape
Tirzepatide vs the leading GLP-1 and the next-gen triple agonist. These are cross-trial estimates — see the note below.
Safety Profile
Reported adverse events across dose groups. Rates are dose-dependent and consistent with the broader GLP-1 drug class — mostly GI-related.
Side effect rates are shown as ranges because they increase with dose. The 5mg group experienced the mildest GI effects while still achieving 15% weight loss. Gradual titration is standard practice to minimize these effects.
Most GI side effects were mild to moderate in severity and resolved over time. The overall discontinuation rate was low — even at the highest dose, 93% of participants completed treatment. Safety profile is consistent with the GLP-1 drug class.
Unlike investigational drugs, tirzepatide has undergone the full FDA review process. The safety profile has been evaluated across multiple Phase 3 SURMOUNT trials with thousands of participants, supporting its approval for both T2D and weight management.
Dosing Protocol
Tirzepatide follows a gradual 4-week escalation protocol. Six dose levels allow clinicians to find each patient's "minimum effective dose" — the goal is meaningful weight loss with acceptable tolerability, not necessarily hitting 15mg.
Beyond Weight Loss
Tirzepatide's impact extends well beyond obesity — it achieved a genuinely historic regulatory milestone in late 2024 and has become the world's top-selling drug.
In December 2024, tirzepatide became the first pharmaceutical treatment ever approved for obstructive sleep apnea (OSA) — a condition affecting an estimated 1 billion people globally. No drug had ever before received FDA approval to treat sleep apnea.
The approval was based on the SURMOUNT-OSA trials, which demonstrated significant reductions in the Apnea-Hypopnea Index (AHI) — the standard measure of breathing disruptions per hour during sleep. A meaningful subset of participants showed near-complete resolution of their sleep apnea, not just improvement.
Tirzepatide's commercial scale is difficult to overstate. By Q3 2025, combined Mounjaro and Zepbound quarterly revenue surpassed $10 billion — overtaking Merck's Keytruda (pembrolizumab) as the world's top-selling pharmaceutical product.
Study Metadata
All data on this page is sourced from the SURMOUNT-1 trial published in NEJM. Full citation below.
Tirzepatide Once Weekly for the Treatment of Obesity
Self-Assessment
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Bottom Line
Separating confirmed findings from open questions about tirzepatide for weight management.
Continue Reading
Calculators, vendor guides, and dosing information for tirzepatide and other weight loss peptides.
Disclaimer: This page is for educational and informational purposes only. It is not medical advice. Tirzepatide is an FDA-approved prescription medication marketed as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management). Always consult with a qualified healthcare provider before starting any medication or treatment protocol. Data sourced from the SURMOUNT-1 trial (NEJM 2022, PMID: 35658024, DOI: 10.1056/NEJMoa2206038).
Head-to-head comparison of Phase 3 trial results at maximum approved doses over comparable timeframes.
Sources: SURMOUNT-1 NEJM 2022 (tirzepatide); STEP-1 NEJM 2021 (semaglutide).
In the SURMOUNT-1 Phase 3 trial, participants on the highest dose (15mg weekly) lost an average of 22.5% of body weight over 72 weeks — approximately 52 lbs on average. At 5mg, participants lost ~15%, and at 10mg, ~19.5%. This makes tirzepatide the most effective FDA-approved weight loss medication currently available.
Most people notice appetite suppression within the first 1–2 weeks of starting tirzepatide. Meaningful weight loss (5%+ of body weight) is typically seen within 8–12 weeks. Maximum weight loss is generally achieved around 52–72 weeks of continuous treatment. Results depend on dose, diet, and individual response.
Tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 receptor agonist, while semaglutide (Ozempic/Wegovy) is a single GLP-1 receptor agonist. Clinical trials show tirzepatide produces greater average weight loss (22.5% vs ~15% for semaglutide) and better blood sugar control. Tirzepatide also tends to have a slightly better tolerability profile at equivalent weight-loss doses.
Yes. Tirzepatide (brand name Zepbound) received FDA approval for chronic weight management in adults with obesity or overweight with at least one weight-related condition in November 2023. It was previously approved as Mounjaro for type 2 diabetes management in 2022.